Table 1.
JoSpA/ERA clinical features.
| Years (y) | Country | Cohort/sample size | Y f/u | SpA #(%) of total cohort | Age onset ±SD or (25%, 75%) or (range) | % Male | % HLA-B27 | % Spine involvede | % periph. Arthritis | % Enthesitis | % Eye | References |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <1982 | Canada | 39 | 1.9 | 39 (100) SEAb | 9.8 (2, 16) | 90 | 72 | 44 exam 28 X-ray SI 15 X-ray TL spine |
74 | 100 | 15 | (18) |
| 1980–1985 | Norway | 175 | 15.3 | 55 (33) ERA | 11.1 ± 2.8 | 65 | 85 | 35 X-ray 47 IBP 75 decreased mobility |
– | – | – | (2) |
| 1997–2000 | Nordic | 410 | 8 | 46 (11.2) ERA 14 (3.4) PsA 63 (15.4) UA |
10.5 (8.6, 12.3) 5.9 (3.2, 7.2) 8.1 (3.5, 11.9) |
65.2 50 28.6 |
72 21 21 |
– | – | – | – | (20, 21) |
| <2001 | England | 246 | 28 | 32 (13.1) ERA 15 (5.3) PsA |
10.0 ± 3.3 9.9 ± 3.3 |
– | – | – | – | – | 28 23 |
(22) |
| 2002–2003 | Germany | 118 | 4 | 118 (100) SpA (mNY or ESSG)b |
– | 73 | 66 | 32 IBP | 96 | 44 | 6.8 | (17) |
| 1994–2006 | India | 235 | >1.5 | 84 (36) ERA 3 (1) PsA 11 (5) UA |
13 (7, 16) 12 (5, 12) 11 (2–15.5) |
91 33 55 |
89d
– 40 |
19 SI, 37 spine 0 18 SI, 20 spine |
– | 37f
0 27 |
8.3 0 0 |
(23) |
| 2000–2006 | Italy | 59 | 3 | 59 (100) ERA | 9.3 (6.5–13.3) | 68 | 66 | 36 IBP or decreased mobility (in 1y) | – | – | – | (24) |
| 2006–2009 | Brazil | 253 | 253 (100) JSpA (ESSG) | 86 | 80 | 60 IBP | 60 lower limb, 20 upper limb | 58 | 25 | (4) | ||
| 1995–2010 | Taiwan | 195 | >1.5 | 73 (37) ERA 3 (1.5) PsA 11 (5) UA |
10.8 (8.9, 12.3) 9.4 (6.2, 10.8) 10.2 (8.7, 15.1) |
85 67 20 |
82 33 0 |
48 SI or lumbar 33 0 |
– | – | 9.6 0 0 |
(25) |
| 1989–2012 | USA | 234 | –a | 234 (100) ERA | – | 72 | 59 |
26 clinical SI 56 MRI |
92 | 75 | 5.6 | (26) |
| 2008–2015 | France | 114 | 2.5 | ERA/JSpAc | 9.6 (6.9, 12.3) | 59 | 43 | 63 (47 with SI, 24 thoracic and 44 lumbar) | 87 | 86 | – | (16) |
| 1993–2018 | Taiwan | 181 | 7.7 | 72 (40) ERA | 11.0 ± 3.2 | 86 | 97 | 16 (clinical or X-ray SI) | – | – | 10 | (27) |
Cohorts/series are listed by years of patient recruitment and nationality in left columns. Unless otherwise indicated, features are cumulative at follow up rather than baseline. ILAR, International League against Rheumatism; ERA, enthesitis related arthritis; PsA, psoriatic arthritis; UA, undifferentiated arthritis. Follow up years refers to mean or median, depending upon the study. For cohorts not describing a specific manifestation (no data) or with insufficient data (based on <1%), the missing data are designated with a dash (–). IBP, inflammatory back pain; SI. sacroiliitis.
Cross-sectional study.
Other JoSpA. SEA, seronegative enthesopathy and arthropathy; ESSG, European Spondyloarthropathy Study Group; Mny, modified New York criteria for ankylosing spondylitis (28).
Physican diagnosed JSpA. At last followup, 92% met clinical criteria for ASAS peripheral SpA and 75% for either ERA or PsA.
Percentages are from 62 patients with ERA and 10 with PsA were tested for HLA-B27.
Description of axial involvement was heterogeneous between sources and included symptoms, clinical assessment, radiology (X-ray), and MRI.
Relatively low proportions of enthesitis in “ERA” are not explained.